Skip to main content
. 2013 Dec 28;19(48):9447–9452. doi: 10.3748/wjg.v19.i48.9447

Table 4.

Late adverse events in the two groups n (%)

Late adverse event NDP group DDP group χ2 P value
Late esophageal injury
0 18 (52.9) 13 (38.2)
I 10 (29.4) 12 (35.3)
II 4 (11.8) 5 (14.7) 2.299 0.681
III 2 (5.9) 3 (8.8)
IV 0 (0) 1 (2.9)
Late lung injury
0 24 (70.6) 20 (58.8)
I 7 (20.6) 8 (23.5)
II 2 (5.9) 4 (11.8) 1.43 0.698
III 1 (2.9) 2 (5.9)
IV 0 (0) 0 (0)

NDP: Nedaplatin; DDP: Cisplatin.